Introduced by Senator Campbell of Windsor District, Senator Condos of Chittenden District and Senator Welch of Windsor District
Subject: Professions and occupations; optometry; state optometry board; formulary committee
Statement of purpose: This bill proposes to: (1) eliminate the formulary committee required to define the specific drugs or classes of drugs and their concentrations and strengths which optometrists may use; (2) eliminate requirements placed on optometrists to disclose certain information to glaucoma patients; and (3) permit the state optometry board authority to identify which therapeutic pharmaceutical agents optometrists may use.
AN ACT RELATING TO THE PRACTICE OF OPTOMETRY
It is hereby enacted by the General Assembly of the State of Vermont:
Sec. 1. 26 V.S.A. § 1728c is amended to read:
§ 1728c. USE OF ORAL THERAPEUTIC PHARMACEUTICAL AGENT;
COMMUNICATION WITH PRIMARY CARE PROVIDER
licensee who employs an oral therapeutic pharmaceutical agent, as identified by
formulary committee established in section 1724 of this title board,
which might prove to have significant systemic adverse reactions or systemic
side effects shall, in a manner consistent with Vermont law, ascertain the risk
of systemic side effects through either a case history or by communicating with
the patient's primary care provider. The licensee shall also communicate with
the patient's primary care provider, or with a physician skilled in diseases of
the eye, when in the professional judgment of the licensee, it is medically
appropriate. The communication shall be noted in the patient's permanent
record. The methodology of communication shall be determined by the licensee.
Sec. 2. REPEAL
26 V.S.A. §§ 1724 (formulary committee for optometrists) and 1728b (disclosure of information by optometrist) are repealed.
The Vermont General Assembly
115 State Street